IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMVa??s DPX Technology

IMV Inc. (IMV) (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that Canadian bioresearch consortium CQDM
has awarded a grant to a collaboration among IMV, Centre de recherche
du CHU de QuA©bec-UniversitA© Laval,
and La Fondation du CHU de
QuA©bec (FCHUQc).

Under the leadership of Yves
Fradet, M.D., professor of surgery and researcher in cancer
immunotherapy, and his team, in collaboration with IMVa??s team , this
project will receive a grant of up to CAN$1.2M from CQDM and CAN$300,000
from the FCHUQc, to develop a novel dual target T cell therapy for an
initial clinical application in bladder cancer.

The work will target immunogenic peptides identified by Dr Fradeta??s team
from the MAGE protein family member A9 (MAGE-A9). This protein is
frequently expressed in various human cancers including bladder, lung,
and kidney.1 These peptides will be combined with selected
immunogenic peptides from the survivin protein composing the DPX-Survivac
T cell drug candidate.

The researchers believe that MAGE-A9 and survivin peptides presented on
the surface of cancer cells can be used to program T cells to destroy
tumors and may represent ideal targets for anti-cancer T cell
immunotherapies. The collaborators will combine these peptides with
IMVa??s proprietary DPX technology to develop a first-in-class dual target
T cell therapy (DPX-SurMAGE).
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2020    »